RECOMBIVAX HB is indicated for vaccination against infection caused by all known subtypes of
hepatitis B virus.

Select safety information

• RECOMBIVAX HB is contraindicated in the presence of hypersensitivity to yeast or any component of the vaccine.
• Any serious active infection including febrile illness is reason for delaying use of the vaccine except when in the opinion of the physician, withholding the vaccine entails a greater risk.
• In 3 clinical studies involving healthy infants and children receiving 3 doses (5 mcg/0.5 mL) of RECOMBIVAX HB, the most frequent complaints (>1% of injections) included irritability, fever
  (>101°F oral equivalent), diarrhea, fatigue/weakness, diminished appetite, and rhinitis. In a study that compared the three-dose regimen (5 mcg) with the two-dose regimen (10 mcg) of the vaccine in adolescents, the overall frequency of adverse reactions was generally similar. For a list of adverse reactions, please read the Prescribing Information.
• In a group of studies involving healthy adults, the most frequent complaints (>1% of injections) in individuals receiving RECOMBIVAX HB included injection-site reactions, fatigue/weakness, headache, fever (>100°F), malaise, nausea, diarrhea, pharyngitis, and upper respiratory infection.
• As with any vaccine, vaccination with RECOMBIVAX HB may not result in seroprotection of all vaccinees.
• Before administering RECOMBIVAX HB, please read the Prescribing Information.

RECOMBIVAX HB is a registered trademark of Merck & Co., Inc.